The Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis

Overview

The objectives of this study are: to confirm the superiority of TAU-284 over placebo after two weeks of administration to pediatric patients with perennial allergic rhinitis and to investigate safety of TAU-284.

Full Title of Study: “A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (A Randomized, Double-blind, Placebo-controlled Study)”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Triple (Participant, Care Provider, Investigator)
  • Study Primary Completion Date: December 2013

Detailed Description

This is a randomized, double-blind, placebo-controlled, 2-arm parallel-group comparative study to confirm the superiority of TAU-284 over placebo after two weeks of administration of TAU-284 (20 mg/day) or placebo to pediatric patients with perennial allergic rhinitis, with "the change from baseline in total nasal symptom score (total score for the three major nasal symptoms [sneezing, rhinorrhea, and nasal congestion])" as the primary endpoint; and to investigate safety of TAU-284.

Interventions

  • Drug: Bepotastine besilate
    • Two TAU-284 5mg tablets will be taken orally twice a day
  • Drug: Placebo
    • Two Placebo tablets will be taken orally twice a day

Arms, Groups and Cohorts

  • Experimental: TAU-284
    • Two TAU-284 5mg tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).
  • Placebo Comparator: Placebo
    • Two placebo tablets will be taken orally twice a day, once after breakfast and once after dinner (or before bed).

Clinical Trial Outcome Measures

Primary Measures

  • Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion]
    • Time Frame: Baseline and Week 2
    • Total score for the three major nasal symptoms (sneezing, rhinorrhea, and nasal congestion) were rated on 5-point scale ranging from 0 (no symptoms) to 4 (very severe).

Secondary Measures

  • Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion]
    • Time Frame: baseline, Week1 and Week 2
  • Change From Baseline in Individual Nasal Symptom Scores (Sneezing, Rhinorrhea, Nasal Congestion, and Impairment in Daily Activities)
    • Time Frame: baseline, Week1 and Week 2
  • Change From Baseline in Individual Scores for Local Nasal Findings (Rhinoscopic Findings)
    • Time Frame: baseline, Week1 and Week 2
  • Change From Baseline in Severity Score for Symptoms of Allergic Rhinitis
    • Time Frame: Randomization, Week1 and Week 2
  • Adverse Events and Adverse Drug Reactions
    • Time Frame: Week 2

Participating in This Clinical Trial

Inclusion Criteria

  • Patients aged between 7 and 15 years – Patients who have received a diagnosis of perennial allergic rhinitis according to the diagnostic criteria – Patients with a mean rhinorrhea score and a mean sneezing score of at least 2 on the basis of symptoms recorded in the nasal allergy diary during the observation period etc. Exclusion Criteria:

  • Patients with vasomotor rhinitis or eosinophilic rhinitis – Patients who have concurrent nasal disease that may affect the efficacy of TAU-284 – Patients with a history of any of the nasal surgical procedures – Patients who have a positive result for pollen antigens which are dispersed during the study period – Patients who have a positive result for dog dander or cat dander antigen and have a chance to touch dogs or cats. – Patients with current or previous history of drug allergy – Patients who concurrently have renal function abnormalities that may cause safety problems etc.

Gender Eligibility: All

Minimum Age: 7 Years

Maximum Age: 15 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Mitsubishi Tanabe Pharma Corporation
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • KIMIHIRO OKUBO, Study Director, Nippon Medical School

Citations Reporting on Results

Okubo K, Ichimura M, Koyama T, Susuta Y, Izaki H. Double-blind placebo-controlled study of bepotastine besilate in pediatric patients with perennial allergic rhinitis. Expert Opin Pharmacother. 2015;16(16):2395-408. doi: 10.1517/14656566.2015.1085511. Epub 2015 Sep 12.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.